Literature DB >> 22230041

The health and economic burden of chickenpox and herpes zoster in Belgium.

J Bilcke1, B Ogunjimi, C Marais, F de Smet, M Callens, K Callaert, E van Kerschaver, J Ramet, P van Damme, P Beutels.   

Abstract

Varicella-zoster virus causes chickenpox (CP) and after reactivation herpes zoster (HZ). Vaccines are available against both diseases warranting an assessment of the pre-vaccination burden of disease. We collected data from relevant Belgian databases and performed five surveys of CP and HZ patients. The rates at which a general practitioner is visited at least once for CP and HZ are 346 and 378/100 000 person-years, respectively. The average CP and HZ hospitalization rates are 5·3 and 14·2/100 000 person-years respectively. The direct medical cost for HZ is about twice as large as the direct medical cost for CP. The quality-adjusted life years lost for ambulatory CP patients consulting a physician is more than double that of those not consulting a physician (0·010 vs. 0·004). In conclusion, both diseases cause a substantial burden in Belgium.

Entities:  

Mesh:

Year:  2012        PMID: 22230041     DOI: 10.1017/S0950268811002640

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  24 in total

Review 1.  Evaluation of the economic burden of Herpes Zoster (HZ) infection.

Authors:  Donatella Panatto; Nicola Luigi Bragazzi; Emanuela Rizzitelli; Paolo Bonanni; Sara Boccalini; Giancarlo Icardi; Roberto Gasparini; Daniela Amicizia
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting?

Authors:  Joke Bilcke; Albert Jan van Hoek; Philippe Beutels
Journal:  Hum Vaccin Immunother       Date:  2013-01-15       Impact factor: 3.452

3.  The Epidemiology of Herpes Zoster After Varicella Immunization Under Different Biological Hypotheses: Perspectives From Mathematical Modeling.

Authors:  Giorgio Guzzetta; Piero Poletti; Stefano Merler; Piero Manfredi
Journal:  Am J Epidemiol       Date:  2016-03-18       Impact factor: 4.897

4.  Perspectives on optimal control of varicella and herpes zoster by mass routine varicella vaccination.

Authors:  Monica Betta; Marco Laurino; Andrea Pugliese; Giorgio Guzzetta; Alberto Landi; Piero Manfredi
Journal:  Proc Biol Sci       Date:  2016-03-16       Impact factor: 5.349

5.  Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine.

Authors:  Zoë Pieters; Benson Ogunjimi; Philippe Beutels; Joke Bilcke
Journal:  Pharmacoeconomics       Date:  2022-01-30       Impact factor: 4.558

Review 6.  Herpes Zoster Risk Reduction through Exposure to Chickenpox Patients: A Systematic Multidisciplinary Review.

Authors:  Benson Ogunjimi; Pierre Van Damme; Philippe Beutels
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

7.  Epidemiological characteristics and societal burden of varicella zoster virus in the Netherlands.

Authors:  Jorien G J Pierik; Pearl D Gumbs; Sander A C Fortanier; Pauline C E Van Steenwijk; Maarten J Postma
Journal:  BMC Infect Dis       Date:  2012-05-10       Impact factor: 3.090

8.  Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries.

Authors:  Piero Poletti; Alessia Melegaro; Marco Ajelli; Emanuele Del Fava; Giorgio Guzzetta; Luca Faustini; Giampaolo Scalia Tomba; Pierluigi Lopalco; Caterina Rizzo; Stefano Merler; Piero Manfredi
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

9.  Increased herpes zoster risk associated with poor HLA-A immediate early 62 protein (IE62) affinity.

Authors:  Pieter Meysman; Nicolas De Neuter; Esther Bartholomeus; George Elias; Johan Van den Bergh; Marie-Paule Emonds; Geert W Haasnoot; Steven Heynderickx; Johan Wens; Nele R Michels; Julien Lambert; Eva Lion; Frans H J Claas; Herman Goossens; Evelien Smits; Pierre Van Damme; Viggo Van Tendeloo; Philippe Beutels; Arvid Suls; Geert Mortier; Kris Laukens; Benson Ogunjimi
Journal:  Immunogenetics       Date:  2017-12-01       Impact factor: 3.330

10.  Integrating between-host transmission and within-host immunity to analyze the impact of varicella vaccination on zoster.

Authors:  Benson Ogunjimi; Lander Willem; Philippe Beutels; Niel Hens
Journal:  Elife       Date:  2015-07-11       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.